Empower Your
Literature Research
Team with AI
Transform Research with A79's Collaborative Literature Review Platform.
Unlock deeper insights and drive faster innovation with AI-powered evidence synthesis.
How A79 helps
A79's AI-powered platform ensures that research is based on the highest quality evidence by automatically deduplicating abstracts, screening citations based on PICO criteria, and enabling collaborative review workflows.
AI-Powered Evidence Synthesis
Understand complex medical topics for faster screening.
Prioritize relevant abstracts for efficient review.
Provide access to a vast range of literary sources.
Powers high-quality, unbiased evidence generation.
Efficacy of immune checkpoint inhibitors
Add to dashboard
Product Information: LYTGOBI (Futibatinib)
Based on the information provided in the table, here's a summary of the feedback and key insights about the product LYTGOBI (Futibatinib):
Efficacy
1. Good response rates and long duration of response:
Patients have shown responses lasting >2 years
Good efficacy reported, making it a go-to option for FGFR2 fusion or gene rearrangement
Exciting response rate and longer duration of response
PFS is longer than anticipated
2. Potential for use in specific patient populations:
• May be used immediately after first-line treatment in patients unable to tolerate Cisplatin
Safety and Adverse Events
1. Nail toxicities:
Streamlined Collaboration & Workflow
Offer a centralized dashboard for team collaboration.
Enable teams to screen, annotate, and track progress.
Support single, dual, and custom review workflows.
Facilitate seamless communication and knowledge sharing.
Found 3 duplicate extracts
Download citations?
Found 4 abstracts
Automated Screening & Analysis
Automatically deduplicate abstracts for a clean dataset.
Surfaces important abstracts and color-codes by PICO.
Allows for easy tagging and downloading of citations.
Accelerates evidence generation and deeper analysis.
The features
Literature Research
teams love
Conversational flow
Ask questions in natural language and receive instant, actionable answers. No coding or complex queries required.
We integrate with internal as well as external data sources to give you the most accurate information.
Request a demo
How many treatments are we evaluating?
What’s the main insight from this data?
Here are the main insights from the data provided:
1. Treatment Preferences in 3rd Line aCRC:
CANCERX + bevacizumab (TFD/PTI + Bev) is widely adopted as the standard of care in 3rd line aCRC treatment
This combination is preferred over monotherapy options
Fruquintinib is emerging as a potential 4th line option or for patients with poor performance status
2. Clinical Experience with CANCERX + Bev:
Generally well-tolerated with manageable side effects
Some practices use growth factor support (WBCS) to manage cytopenlas
Alternate dosing schedules (e.g., biweekly) are sometimes used to manage toxicity
3. Biomarker Testing:
cDNA testing is gaining interest but its clinical utility is still being evaluated
Some KOLs are cautious about over-reliance on cIDNA for treatment decisions
GPA (genomic profile analysis) testing practices vary among oncologists.
Your data includes 5 treatments. What would you like to explore next?
Advanced Filters
Drill down into your data with powerful filters that isolate specific cohorts, time frames, and variables.
Charts
Transform your data into compelling visuals that reveal hidden trends and patterns. Easily customize and share your insights.
Case studies
See A79 in Action
Discover how A79 is driving measurable productivity improvements for our partners
The platform's AI-powered insights allow us to tailor our medical communications and deliver the right information to the right audience at the right time. This has significantly improved our engagement and strengthened our relationships with key opinion leaders.
Head of Medical Affairs
Leading Pharmaceutical Company
A79 has been a true partner in our AI journey, working hand-in-hand with us to build custom solutions that are not only powerful but also incredibly user-friendly. The platform has been enthusiastically embraced by our entire team.
Head of AI development
Leading Oncology Company
A79 has completely transformed my workflow. I can now access critical scientific information, prepare for HCP interactions, and generate insightful reports in a fraction of the time it used to take.
Senior MSL
Top 20 Pharma
Ready to Unlock Faster Insights?
Discover how A79 can transform your data analysis process.
Copyright A79® 2024